nodes	percent_of_prediction	percent_of_DWPC	metapath
Loxapine—CHRM3—muscle of abdomen—ovarian cancer	0.0263	0.116	CbGeAlD
Loxapine—HTR7—vein—ovarian cancer	0.0193	0.0848	CbGeAlD
Loxapine—HTR2A—vein—ovarian cancer	0.012	0.0529	CbGeAlD
Loxapine—HTR1E—myometrium—ovarian cancer	0.0104	0.0458	CbGeAlD
Loxapine—HRH4—bone marrow—ovarian cancer	0.0098	0.043	CbGeAlD
Loxapine—DRD4—testis—ovarian cancer	0.00568	0.025	CbGeAlD
Loxapine—CHRM5—epithelium—ovarian cancer	0.0056	0.0246	CbGeAlD
Loxapine—HTR1E—female gonad—ovarian cancer	0.00553	0.0243	CbGeAlD
Loxapine—DRD5—female reproductive system—ovarian cancer	0.00464	0.0204	CbGeAlD
Loxapine—CHRM4—testis—ovarian cancer	0.0043	0.0189	CbGeAlD
Loxapine—DRD5—female gonad—ovarian cancer	0.00422	0.0185	CbGeAlD
Loxapine—ADRA2C—myometrium—ovarian cancer	0.00349	0.0153	CbGeAlD
Loxapine—HTR7—epithelium—ovarian cancer	0.00298	0.0131	CbGeAlD
Loxapine—SLC6A2—decidua—ovarian cancer	0.00292	0.0128	CbGeAlD
Loxapine—ADRA1A—epithelium—ovarian cancer	0.00288	0.0126	CbGeAlD
Loxapine—HTR1B—female reproductive system—ovarian cancer	0.00287	0.0126	CbGeAlD
Loxapine—HRH1—myometrium—ovarian cancer	0.00284	0.0125	CbGeAlD
Loxapine—ADRA2A—myometrium—ovarian cancer	0.00279	0.0122	CbGeAlD
Loxapine—HTR1D—female reproductive system—ovarian cancer	0.00278	0.0122	CbGeAlD
Loxapine—HTR2C—female reproductive system—ovarian cancer	0.00275	0.0121	CbGeAlD
Loxapine—ADRA2C—uterine cervix—ovarian cancer	0.00272	0.0119	CbGeAlD
Loxapine—ADRB1—female reproductive system—ovarian cancer	0.0027	0.0119	CbGeAlD
Loxapine—SLC6A4—female reproductive system—ovarian cancer	0.00261	0.0115	CbGeAlD
Loxapine—CHRM1—female reproductive system—ovarian cancer	0.0026	0.0114	CbGeAlD
Loxapine—ADRA2C—decidua—ovarian cancer	0.00259	0.0114	CbGeAlD
Loxapine—SLC6A2—gonad—ovarian cancer	0.00257	0.0113	CbGeAlD
Loxapine—HRH2—lymph node—ovarian cancer	0.00255	0.0112	CbGeAlD
Loxapine—HTR7—gonad—ovarian cancer	0.00248	0.0109	CbGeAlD
Loxapine—ADRA2C—endometrium—ovarian cancer	0.00246	0.0108	CbGeAlD
Loxapine—CHRM3—female reproductive system—ovarian cancer	0.00233	0.0102	CbGeAlD
Loxapine—SLC6A3—testis—ovarian cancer	0.0023	0.0101	CbGeAlD
Loxapine—SLC6A2—female reproductive system—ovarian cancer	0.0023	0.0101	CbGeAlD
Loxapine—HTR2A—embryo—ovarian cancer	0.00228	0.01	CbGeAlD
Loxapine—ADRA2C—uterus—ovarian cancer	0.00226	0.00995	CbGeAlD
Loxapine—HRH1—epithelium—ovarian cancer	0.00223	0.00978	CbGeAlD
Loxapine—HTR7—female reproductive system—ovarian cancer	0.00222	0.00973	CbGeAlD
Loxapine—HRH1—uterine cervix—ovarian cancer	0.00221	0.0097	CbGeAlD
Loxapine—ADRA2A—uterine cervix—ovarian cancer	0.00217	0.00953	CbGeAlD
Loxapine—CHRM3—female gonad—ovarian cancer	0.00212	0.0093	CbGeAlD
Loxapine—HRH1—decidua—ovarian cancer	0.0021	0.00924	CbGeAlD
Loxapine—ADRA2A—decidua—ovarian cancer	0.00207	0.00908	CbGeAlD
Loxapine—HRH1—endometrium—ovarian cancer	0.002	0.00877	CbGeAlD
Loxapine—ADRA2A—endometrium—ovarian cancer	0.00196	0.00862	CbGeAlD
Loxapine—CHRM3—testis—ovarian cancer	0.00188	0.00825	CbGeAlD
Loxapine—HTR2A—epithelium—ovarian cancer	0.00186	0.00817	CbGeAlD
Loxapine—SLC6A2—testis—ovarian cancer	0.00185	0.00815	CbGeAlD
Loxapine—ADRA2C—female gonad—ovarian cancer	0.00185	0.00814	CbGeAlD
Loxapine—ADRA2C—vagina—ovarian cancer	0.00184	0.00809	CbGeAlD
Loxapine—ADRA2A—gonad—ovarian cancer	0.00182	0.00799	CbGeAlD
Loxapine—ADRA2A—uterus—ovarian cancer	0.00181	0.00794	CbGeAlD
Loxapine—HTR7—testis—ovarian cancer	0.00179	0.00785	CbGeAlD
Loxapine—Chest pain—Vinorelbine—ovarian cancer	0.00171	0.00307	CcSEcCtD
Loxapine—Dyspnoea—Topotecan—ovarian cancer	0.00171	0.00307	CcSEcCtD
Loxapine—Renal failure—Paclitaxel—ovarian cancer	0.0017	0.00305	CcSEcCtD
Loxapine—DRD2—testis—ovarian cancer	0.00169	0.00743	CbGeAlD
Loxapine—Paraesthesia—Melphalan—ovarian cancer	0.00169	0.00303	CcSEcCtD
Loxapine—Gait disturbance—Doxorubicin—ovarian cancer	0.00168	0.00301	CcSEcCtD
Loxapine—Dyspnoea—Melphalan—ovarian cancer	0.00167	0.00301	CcSEcCtD
Loxapine—Gastrointestinal disorder—Topotecan—ovarian cancer	0.00166	0.00297	CcSEcCtD
Loxapine—HRH1—female reproductive system—ovarian cancer	0.00165	0.00727	CbGeAlD
Loxapine—Fatigue—Topotecan—ovarian cancer	0.00165	0.00297	CcSEcCtD
Loxapine—Dysphagia—Docetaxel—ovarian cancer	0.00165	0.00295	CcSEcCtD
Loxapine—ADRA2C—testis—ovarian cancer	0.00164	0.00722	CbGeAlD
Loxapine—Constipation—Topotecan—ovarian cancer	0.00164	0.00294	CcSEcCtD
Loxapine—Hepatocellular injury—Doxorubicin—ovarian cancer	0.00164	0.00294	CcSEcCtD
Loxapine—Dry eye—Epirubicin—ovarian cancer	0.00163	0.00293	CcSEcCtD
Loxapine—ADRA2A—female reproductive system—ovarian cancer	0.00162	0.00714	CbGeAlD
Loxapine—Gastrointestinal disorder—Melphalan—ovarian cancer	0.00162	0.00291	CcSEcCtD
Loxapine—Fatigue—Melphalan—ovarian cancer	0.00162	0.00291	CcSEcCtD
Loxapine—Bronchospasm—Docetaxel—ovarian cancer	0.00162	0.0029	CcSEcCtD
Loxapine—Nervous system disorder—Vinorelbine—ovarian cancer	0.00161	0.00289	CcSEcCtD
Loxapine—Thrombocytopenia—Vinorelbine—ovarian cancer	0.00161	0.00288	CcSEcCtD
Loxapine—Tachycardia—Vinorelbine—ovarian cancer	0.0016	0.00288	CcSEcCtD
Loxapine—Salivary hypersecretion—Doxorubicin—ovarian cancer	0.00159	0.00285	CcSEcCtD
Loxapine—Hypersensitivity—Chlorambucil—ovarian cancer	0.00159	0.00285	CcSEcCtD
Loxapine—Feeling abnormal—Topotecan—ovarian cancer	0.00158	0.00284	CcSEcCtD
Loxapine—HTR2A—gonad—ovarian cancer	0.00155	0.0068	CbGeAlD
Loxapine—Asthenia—Chlorambucil—ovarian cancer	0.00155	0.00278	CcSEcCtD
Loxapine—Hypoaesthesia—Paclitaxel—ovarian cancer	0.00155	0.00277	CcSEcCtD
Loxapine—Hypotension—Vinorelbine—ovarian cancer	0.00153	0.00275	CcSEcCtD
Loxapine—Pruritus—Chlorambucil—ovarian cancer	0.00152	0.00274	CcSEcCtD
Loxapine—Dry eye—Doxorubicin—ovarian cancer	0.00151	0.00271	CcSEcCtD
Loxapine—HRH1—female gonad—ovarian cancer	0.00151	0.00661	CbGeAlD
Loxapine—Weight increased—Docetaxel—ovarian cancer	0.0015	0.00269	CcSEcCtD
Loxapine—HRH1—vagina—ovarian cancer	0.0015	0.00657	CbGeAlD
Loxapine—Weight decreased—Docetaxel—ovarian cancer	0.00149	0.00267	CcSEcCtD
Loxapine—ADRA2A—female gonad—ovarian cancer	0.00148	0.00649	CbGeAlD
Loxapine—Paraesthesia—Vinorelbine—ovarian cancer	0.00147	0.00265	CcSEcCtD
Loxapine—ADRA2A—vagina—ovarian cancer	0.00147	0.00645	CbGeAlD
Loxapine—Dyspnoea—Vinorelbine—ovarian cancer	0.00146	0.00263	CcSEcCtD
Loxapine—Photosensitivity—Epirubicin—ovarian cancer	0.00146	0.00262	CcSEcCtD
Loxapine—Renal failure—Docetaxel—ovarian cancer	0.00144	0.00259	CcSEcCtD
Loxapine—Jaundice—Docetaxel—ovarian cancer	0.00143	0.00257	CcSEcCtD
Loxapine—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.00142	0.00254	CcSEcCtD
Loxapine—Fatigue—Vinorelbine—ovarian cancer	0.00141	0.00254	CcSEcCtD
Loxapine—Hypersensitivity—Topotecan—ovarian cancer	0.00141	0.00254	CcSEcCtD
Loxapine—Angiopathy—Paclitaxel—ovarian cancer	0.00141	0.00253	CcSEcCtD
Loxapine—Constipation—Vinorelbine—ovarian cancer	0.0014	0.00252	CcSEcCtD
Loxapine—Mediastinal disorder—Paclitaxel—ovarian cancer	0.0014	0.00251	CcSEcCtD
Loxapine—Hypersensitivity—Melphalan—ovarian cancer	0.00138	0.00248	CcSEcCtD
Loxapine—HTR2A—female reproductive system—ovarian cancer	0.00138	0.00607	CbGeAlD
Loxapine—Asthenia—Topotecan—ovarian cancer	0.00138	0.00247	CcSEcCtD
Loxapine—Alopecia—Paclitaxel—ovarian cancer	0.00137	0.00246	CcSEcCtD
Loxapine—Vomiting—Chlorambucil—ovarian cancer	0.00137	0.00246	CcSEcCtD
Loxapine—Agranulocytosis—Docetaxel—ovarian cancer	0.00137	0.00246	CcSEcCtD
Loxapine—Pruritus—Topotecan—ovarian cancer	0.00136	0.00244	CcSEcCtD
Loxapine—Photosensitivity—Doxorubicin—ovarian cancer	0.00135	0.00243	CcSEcCtD
Loxapine—Feeling abnormal—Vinorelbine—ovarian cancer	0.00135	0.00243	CcSEcCtD
Loxapine—Asthenia—Melphalan—ovarian cancer	0.00135	0.00242	CcSEcCtD
Loxapine—SLC6A2—lymph node—ovarian cancer	0.00134	0.00591	CbGeAlD
Loxapine—HRH1—testis—ovarian cancer	0.00133	0.00586	CbGeAlD
Loxapine—Pruritus—Melphalan—ovarian cancer	0.00133	0.00239	CcSEcCtD
Loxapine—Tension—Paclitaxel—ovarian cancer	0.00133	0.00238	CcSEcCtD
Loxapine—Dysgeusia—Paclitaxel—ovarian cancer	0.00132	0.00238	CcSEcCtD
Loxapine—Hepatitis—Docetaxel—ovarian cancer	0.00132	0.00236	CcSEcCtD
Loxapine—ADRA2A—testis—ovarian cancer	0.00131	0.00576	CbGeAlD
Loxapine—Hypoaesthesia—Docetaxel—ovarian cancer	0.00131	0.00235	CcSEcCtD
Loxapine—Cerebrovascular accident—Epirubicin—ovarian cancer	0.00131	0.00235	CcSEcCtD
Loxapine—Muscle spasms—Paclitaxel—ovarian cancer	0.0013	0.00233	CcSEcCtD
Loxapine—Nausea—Chlorambucil—ovarian cancer	0.00128	0.0023	CcSEcCtD
Loxapine—Vision blurred—Paclitaxel—ovarian cancer	0.00127	0.00229	CcSEcCtD
Loxapine—Dizziness—Topotecan—ovarian cancer	0.00127	0.00228	CcSEcCtD
Loxapine—Tremor—Paclitaxel—ovarian cancer	0.00127	0.00227	CcSEcCtD
Loxapine—HTR2A—vagina—ovarian cancer	0.00125	0.00549	CbGeAlD
Loxapine—Agitation—Paclitaxel—ovarian cancer	0.00124	0.00223	CcSEcCtD
Loxapine—Vomiting—Topotecan—ovarian cancer	0.00122	0.00219	CcSEcCtD
Loxapine—Syncope—Paclitaxel—ovarian cancer	0.00121	0.00218	CcSEcCtD
Loxapine—Cerebrovascular accident—Doxorubicin—ovarian cancer	0.00121	0.00218	CcSEcCtD
Loxapine—Leukopenia—Paclitaxel—ovarian cancer	0.00121	0.00217	CcSEcCtD
Loxapine—Rash—Topotecan—ovarian cancer	0.00121	0.00217	CcSEcCtD
Loxapine—Hypersensitivity—Vinorelbine—ovarian cancer	0.00121	0.00217	CcSEcCtD
Loxapine—Dermatitis—Topotecan—ovarian cancer	0.00121	0.00217	CcSEcCtD
Loxapine—Headache—Topotecan—ovarian cancer	0.0012	0.00216	CcSEcCtD
Loxapine—Angiopathy—Docetaxel—ovarian cancer	0.00119	0.00214	CcSEcCtD
Loxapine—Vomiting—Melphalan—ovarian cancer	0.00119	0.00214	CcSEcCtD
Loxapine—ADRA2C—lymph node—ovarian cancer	0.00119	0.00523	CbGeAlD
Loxapine—Loss of consciousness—Paclitaxel—ovarian cancer	0.00119	0.00213	CcSEcCtD
Loxapine—Mediastinal disorder—Docetaxel—ovarian cancer	0.00119	0.00213	CcSEcCtD
Loxapine—Rash—Melphalan—ovarian cancer	0.00118	0.00213	CcSEcCtD
Loxapine—Dermatitis—Melphalan—ovarian cancer	0.00118	0.00212	CcSEcCtD
Loxapine—Cough—Paclitaxel—ovarian cancer	0.00118	0.00212	CcSEcCtD
Loxapine—Asthenia—Vinorelbine—ovarian cancer	0.00118	0.00211	CcSEcCtD
Loxapine—Orthostatic hypotension—Epirubicin—ovarian cancer	0.00117	0.00211	CcSEcCtD
Loxapine—Convulsion—Paclitaxel—ovarian cancer	0.00117	0.0021	CcSEcCtD
Loxapine—Hypertension—Paclitaxel—ovarian cancer	0.00117	0.0021	CcSEcCtD
Loxapine—Alopecia—Docetaxel—ovarian cancer	0.00116	0.00209	CcSEcCtD
Loxapine—Pruritus—Vinorelbine—ovarian cancer	0.00116	0.00208	CcSEcCtD
Loxapine—Chest pain—Paclitaxel—ovarian cancer	0.00115	0.00207	CcSEcCtD
Loxapine—Nausea—Topotecan—ovarian cancer	0.00114	0.00205	CcSEcCtD
Loxapine—Dry mouth—Paclitaxel—ovarian cancer	0.00113	0.00202	CcSEcCtD
Loxapine—Dysgeusia—Docetaxel—ovarian cancer	0.00112	0.00202	CcSEcCtD
Loxapine—Nausea—Melphalan—ovarian cancer	0.00112	0.002	CcSEcCtD
Loxapine—HTR2A—testis—ovarian cancer	0.00111	0.0049	CbGeAlD
Loxapine—Confusional state—Paclitaxel—ovarian cancer	0.00111	0.002	CcSEcCtD
Loxapine—Dysphagia—Epirubicin—ovarian cancer	0.00111	0.00199	CcSEcCtD
Loxapine—Oedema—Paclitaxel—ovarian cancer	0.0011	0.00198	CcSEcCtD
Loxapine—Muscle spasms—Docetaxel—ovarian cancer	0.0011	0.00198	CcSEcCtD
Loxapine—Shock—Paclitaxel—ovarian cancer	0.00109	0.00195	CcSEcCtD
Loxapine—Dizziness—Vinorelbine—ovarian cancer	0.00109	0.00195	CcSEcCtD
Loxapine—Orthostatic hypotension—Doxorubicin—ovarian cancer	0.00108	0.00195	CcSEcCtD
Loxapine—Nervous system disorder—Paclitaxel—ovarian cancer	0.00108	0.00194	CcSEcCtD
Loxapine—Thrombocytopenia—Paclitaxel—ovarian cancer	0.00108	0.00194	CcSEcCtD
Loxapine—Tachycardia—Paclitaxel—ovarian cancer	0.00108	0.00193	CcSEcCtD
Loxapine—Vomiting—Vinorelbine—ovarian cancer	0.00104	0.00187	CcSEcCtD
Loxapine—Rash—Vinorelbine—ovarian cancer	0.00103	0.00186	CcSEcCtD
Loxapine—Dermatitis—Vinorelbine—ovarian cancer	0.00103	0.00186	CcSEcCtD
Loxapine—Hypotension—Paclitaxel—ovarian cancer	0.00103	0.00185	CcSEcCtD
Loxapine—Headache—Vinorelbine—ovarian cancer	0.00103	0.00185	CcSEcCtD
Loxapine—Syncope—Docetaxel—ovarian cancer	0.00103	0.00185	CcSEcCtD
Loxapine—Dysphagia—Doxorubicin—ovarian cancer	0.00103	0.00184	CcSEcCtD
Loxapine—Leukopenia—Docetaxel—ovarian cancer	0.00103	0.00184	CcSEcCtD
Loxapine—Photosensitivity reaction—Epirubicin—ovarian cancer	0.00101	0.00182	CcSEcCtD
Loxapine—Weight increased—Epirubicin—ovarian cancer	0.00101	0.00181	CcSEcCtD
Loxapine—Loss of consciousness—Docetaxel—ovarian cancer	0.00101	0.00181	CcSEcCtD
Loxapine—Weight decreased—Epirubicin—ovarian cancer	0.001	0.0018	CcSEcCtD
Loxapine—Cough—Docetaxel—ovarian cancer	0.001	0.0018	CcSEcCtD
Loxapine—Insomnia—Paclitaxel—ovarian cancer	0.000998	0.00179	CcSEcCtD
Loxapine—Convulsion—Docetaxel—ovarian cancer	0.000993	0.00178	CcSEcCtD
Loxapine—Paraesthesia—Paclitaxel—ovarian cancer	0.000991	0.00178	CcSEcCtD
Loxapine—Hypertension—Docetaxel—ovarian cancer	0.00099	0.00178	CcSEcCtD
Loxapine—Drowsiness—Epirubicin—ovarian cancer	0.000989	0.00178	CcSEcCtD
Loxapine—Dyspnoea—Paclitaxel—ovarian cancer	0.000984	0.00177	CcSEcCtD
Loxapine—Somnolence—Paclitaxel—ovarian cancer	0.000981	0.00176	CcSEcCtD
Loxapine—Chest pain—Docetaxel—ovarian cancer	0.000976	0.00175	CcSEcCtD
Loxapine—Nausea—Vinorelbine—ovarian cancer	0.000975	0.00175	CcSEcCtD
Loxapine—Renal failure—Epirubicin—ovarian cancer	0.000973	0.00175	CcSEcCtD
Loxapine—HRH1—lymph node—ovarian cancer	0.000968	0.00425	CbGeAlD
Loxapine—Jaundice—Epirubicin—ovarian cancer	0.000964	0.00173	CcSEcCtD
Loxapine—Dry mouth—Docetaxel—ovarian cancer	0.000954	0.00171	CcSEcCtD
Loxapine—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000953	0.00171	CcSEcCtD
Loxapine—Fatigue—Paclitaxel—ovarian cancer	0.000952	0.00171	CcSEcCtD
Loxapine—ADRA2A—lymph node—ovarian cancer	0.00095	0.00418	CbGeAlD
Loxapine—Constipation—Paclitaxel—ovarian cancer	0.000944	0.00169	CcSEcCtD
Loxapine—Confusional state—Docetaxel—ovarian cancer	0.000943	0.00169	CcSEcCtD
Loxapine—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000937	0.00168	CcSEcCtD
Loxapine—Oedema—Docetaxel—ovarian cancer	0.000935	0.00168	CcSEcCtD
Loxapine—Weight increased—Doxorubicin—ovarian cancer	0.000934	0.00168	CcSEcCtD
Loxapine—Weight decreased—Doxorubicin—ovarian cancer	0.000929	0.00167	CcSEcCtD
Loxapine—Agranulocytosis—Epirubicin—ovarian cancer	0.000923	0.00166	CcSEcCtD
Loxapine—Shock—Docetaxel—ovarian cancer	0.00092	0.00165	CcSEcCtD
Loxapine—Nervous system disorder—Docetaxel—ovarian cancer	0.000917	0.00165	CcSEcCtD
Loxapine—Thrombocytopenia—Docetaxel—ovarian cancer	0.000916	0.00164	CcSEcCtD
Loxapine—Drowsiness—Doxorubicin—ovarian cancer	0.000915	0.00164	CcSEcCtD
Loxapine—Tachycardia—Docetaxel—ovarian cancer	0.000913	0.00164	CcSEcCtD
Loxapine—Feeling abnormal—Paclitaxel—ovarian cancer	0.000909	0.00163	CcSEcCtD
Loxapine—Renal failure—Doxorubicin—ovarian cancer	0.0009	0.00162	CcSEcCtD
Loxapine—Jaundice—Doxorubicin—ovarian cancer	0.000892	0.0016	CcSEcCtD
Loxapine—Hepatitis—Epirubicin—ovarian cancer	0.000888	0.00159	CcSEcCtD
Loxapine—Hypoaesthesia—Epirubicin—ovarian cancer	0.000884	0.00159	CcSEcCtD
Loxapine—Clozapine—CYP1B1—ovarian cancer	0.000875	0.223	CrCbGaD
Loxapine—Hypotension—Docetaxel—ovarian cancer	0.000874	0.00157	CcSEcCtD
Loxapine—Agranulocytosis—Doxorubicin—ovarian cancer	0.000854	0.00153	CcSEcCtD
Loxapine—Insomnia—Docetaxel—ovarian cancer	0.000846	0.00152	CcSEcCtD
Loxapine—Paraesthesia—Docetaxel—ovarian cancer	0.00084	0.00151	CcSEcCtD
Loxapine—Dyspnoea—Docetaxel—ovarian cancer	0.000834	0.0015	CcSEcCtD
Loxapine—Somnolence—Docetaxel—ovarian cancer	0.000832	0.00149	CcSEcCtD
Loxapine—Hepatitis—Doxorubicin—ovarian cancer	0.000822	0.00148	CcSEcCtD
Loxapine—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000818	0.00147	CcSEcCtD
Loxapine—Hypersensitivity—Paclitaxel—ovarian cancer	0.000813	0.00146	CcSEcCtD
Loxapine—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000808	0.00145	CcSEcCtD
Loxapine—Fatigue—Docetaxel—ovarian cancer	0.000807	0.00145	CcSEcCtD
Loxapine—Angiopathy—Epirubicin—ovarian cancer	0.000806	0.00145	CcSEcCtD
Loxapine—Mediastinal disorder—Epirubicin—ovarian cancer	0.0008	0.00144	CcSEcCtD
Loxapine—Constipation—Docetaxel—ovarian cancer	0.0008	0.00144	CcSEcCtD
Loxapine—Asthenia—Paclitaxel—ovarian cancer	0.000792	0.00142	CcSEcCtD
Loxapine—Alopecia—Epirubicin—ovarian cancer	0.000785	0.00141	CcSEcCtD
Loxapine—Pruritus—Paclitaxel—ovarian cancer	0.000781	0.0014	CcSEcCtD
Loxapine—Feeling abnormal—Docetaxel—ovarian cancer	0.000771	0.00138	CcSEcCtD
Loxapine—Tension—Epirubicin—ovarian cancer	0.000759	0.00136	CcSEcCtD
Loxapine—Dysgeusia—Epirubicin—ovarian cancer	0.000757	0.00136	CcSEcCtD
Loxapine—Angiopathy—Doxorubicin—ovarian cancer	0.000746	0.00134	CcSEcCtD
Loxapine—Muscle spasms—Epirubicin—ovarian cancer	0.000743	0.00133	CcSEcCtD
Loxapine—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000741	0.00133	CcSEcCtD
Loxapine—Dizziness—Paclitaxel—ovarian cancer	0.00073	0.00131	CcSEcCtD
Loxapine—Vision blurred—Epirubicin—ovarian cancer	0.000729	0.00131	CcSEcCtD
Loxapine—Alopecia—Doxorubicin—ovarian cancer	0.000726	0.0013	CcSEcCtD
Loxapine—Agitation—Epirubicin—ovarian cancer	0.00071	0.00128	CcSEcCtD
Loxapine—Tension—Doxorubicin—ovarian cancer	0.000702	0.00126	CcSEcCtD
Loxapine—Vomiting—Paclitaxel—ovarian cancer	0.000702	0.00126	CcSEcCtD
Loxapine—Dysgeusia—Doxorubicin—ovarian cancer	0.000701	0.00126	CcSEcCtD
Loxapine—Rash—Paclitaxel—ovarian cancer	0.000696	0.00125	CcSEcCtD
Loxapine—Dermatitis—Paclitaxel—ovarian cancer	0.000695	0.00125	CcSEcCtD
Loxapine—Syncope—Epirubicin—ovarian cancer	0.000693	0.00124	CcSEcCtD
Loxapine—Leukopenia—Epirubicin—ovarian cancer	0.000692	0.00124	CcSEcCtD
Loxapine—Headache—Paclitaxel—ovarian cancer	0.000691	0.00124	CcSEcCtD
Loxapine—Hypersensitivity—Docetaxel—ovarian cancer	0.000689	0.00124	CcSEcCtD
Loxapine—Muscle spasms—Doxorubicin—ovarian cancer	0.000688	0.00123	CcSEcCtD
Loxapine—Loss of consciousness—Epirubicin—ovarian cancer	0.00068	0.00122	CcSEcCtD
Loxapine—Cough—Epirubicin—ovarian cancer	0.000675	0.00121	CcSEcCtD
Loxapine—Vision blurred—Doxorubicin—ovarian cancer	0.000674	0.00121	CcSEcCtD
Loxapine—Asthenia—Docetaxel—ovarian cancer	0.000671	0.0012	CcSEcCtD
Loxapine—Convulsion—Epirubicin—ovarian cancer	0.00067	0.0012	CcSEcCtD
Loxapine—Hypertension—Epirubicin—ovarian cancer	0.000667	0.0012	CcSEcCtD
Loxapine—Pruritus—Docetaxel—ovarian cancer	0.000662	0.00119	CcSEcCtD
Loxapine—Chest pain—Epirubicin—ovarian cancer	0.000658	0.00118	CcSEcCtD
Loxapine—Agitation—Doxorubicin—ovarian cancer	0.000657	0.00118	CcSEcCtD
Loxapine—Nausea—Paclitaxel—ovarian cancer	0.000656	0.00118	CcSEcCtD
Loxapine—Dry mouth—Epirubicin—ovarian cancer	0.000644	0.00116	CcSEcCtD
Loxapine—Syncope—Doxorubicin—ovarian cancer	0.000642	0.00115	CcSEcCtD
Loxapine—Leukopenia—Doxorubicin—ovarian cancer	0.00064	0.00115	CcSEcCtD
Loxapine—Confusional state—Epirubicin—ovarian cancer	0.000636	0.00114	CcSEcCtD
Loxapine—Oedema—Epirubicin—ovarian cancer	0.000631	0.00113	CcSEcCtD
Loxapine—Loss of consciousness—Doxorubicin—ovarian cancer	0.000629	0.00113	CcSEcCtD
Loxapine—Cough—Doxorubicin—ovarian cancer	0.000624	0.00112	CcSEcCtD
Loxapine—Shock—Epirubicin—ovarian cancer	0.000621	0.00111	CcSEcCtD
Loxapine—Convulsion—Doxorubicin—ovarian cancer	0.00062	0.00111	CcSEcCtD
Loxapine—Nervous system disorder—Epirubicin—ovarian cancer	0.000619	0.00111	CcSEcCtD
Loxapine—Dizziness—Docetaxel—ovarian cancer	0.000619	0.00111	CcSEcCtD
Loxapine—Thrombocytopenia—Epirubicin—ovarian cancer	0.000618	0.00111	CcSEcCtD
Loxapine—Hypertension—Doxorubicin—ovarian cancer	0.000618	0.00111	CcSEcCtD
Loxapine—Tachycardia—Epirubicin—ovarian cancer	0.000616	0.00111	CcSEcCtD
Loxapine—Chest pain—Doxorubicin—ovarian cancer	0.000609	0.00109	CcSEcCtD
Loxapine—Dry mouth—Doxorubicin—ovarian cancer	0.000596	0.00107	CcSEcCtD
Loxapine—Vomiting—Docetaxel—ovarian cancer	0.000595	0.00107	CcSEcCtD
Loxapine—Rash—Docetaxel—ovarian cancer	0.00059	0.00106	CcSEcCtD
Loxapine—Hypotension—Epirubicin—ovarian cancer	0.00059	0.00106	CcSEcCtD
Loxapine—Dermatitis—Docetaxel—ovarian cancer	0.000589	0.00106	CcSEcCtD
Loxapine—Confusional state—Doxorubicin—ovarian cancer	0.000589	0.00106	CcSEcCtD
Loxapine—Headache—Docetaxel—ovarian cancer	0.000586	0.00105	CcSEcCtD
Loxapine—Oedema—Doxorubicin—ovarian cancer	0.000584	0.00105	CcSEcCtD
Loxapine—Shock—Doxorubicin—ovarian cancer	0.000574	0.00103	CcSEcCtD
Loxapine—Nervous system disorder—Doxorubicin—ovarian cancer	0.000573	0.00103	CcSEcCtD
Loxapine—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000572	0.00103	CcSEcCtD
Loxapine—Insomnia—Epirubicin—ovarian cancer	0.000571	0.00102	CcSEcCtD
Loxapine—Tachycardia—Doxorubicin—ovarian cancer	0.00057	0.00102	CcSEcCtD
Loxapine—Paraesthesia—Epirubicin—ovarian cancer	0.000567	0.00102	CcSEcCtD
Loxapine—Dyspnoea—Epirubicin—ovarian cancer	0.000563	0.00101	CcSEcCtD
Loxapine—Somnolence—Epirubicin—ovarian cancer	0.000561	0.00101	CcSEcCtD
Loxapine—Azelastine—ABCB1—ovarian cancer	0.00056	0.143	CrCbGaD
Loxapine—Nausea—Docetaxel—ovarian cancer	0.000556	0.000998	CcSEcCtD
Loxapine—Hypotension—Doxorubicin—ovarian cancer	0.000546	0.000979	CcSEcCtD
Loxapine—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000545	0.000978	CcSEcCtD
Loxapine—Fatigue—Epirubicin—ovarian cancer	0.000544	0.000977	CcSEcCtD
Loxapine—Constipation—Epirubicin—ovarian cancer	0.00054	0.000969	CcSEcCtD
Loxapine—Insomnia—Doxorubicin—ovarian cancer	0.000528	0.000948	CcSEcCtD
Loxapine—Paraesthesia—Doxorubicin—ovarian cancer	0.000524	0.000941	CcSEcCtD
Loxapine—Dyspnoea—Doxorubicin—ovarian cancer	0.000521	0.000934	CcSEcCtD
Loxapine—Feeling abnormal—Epirubicin—ovarian cancer	0.00052	0.000933	CcSEcCtD
Loxapine—Somnolence—Doxorubicin—ovarian cancer	0.000519	0.000932	CcSEcCtD
Loxapine—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000504	0.000905	CcSEcCtD
Loxapine—Fatigue—Doxorubicin—ovarian cancer	0.000503	0.000904	CcSEcCtD
Loxapine—Constipation—Doxorubicin—ovarian cancer	0.000499	0.000896	CcSEcCtD
Loxapine—Feeling abnormal—Doxorubicin—ovarian cancer	0.000481	0.000864	CcSEcCtD
Loxapine—Olanzapine—ABCB1—ovarian cancer	0.000481	0.123	CrCbGaD
Loxapine—Hypersensitivity—Epirubicin—ovarian cancer	0.000465	0.000835	CcSEcCtD
Loxapine—Trazodone—ABCB1—ovarian cancer	0.000465	0.119	CrCbGaD
Loxapine—Asthenia—Epirubicin—ovarian cancer	0.000453	0.000813	CcSEcCtD
Loxapine—Pruritus—Epirubicin—ovarian cancer	0.000446	0.000801	CcSEcCtD
Loxapine—Clobazam—ABCB1—ovarian cancer	0.000435	0.111	CrCbGaD
Loxapine—Hypersensitivity—Doxorubicin—ovarian cancer	0.00043	0.000772	CcSEcCtD
Loxapine—Asthenia—Doxorubicin—ovarian cancer	0.000419	0.000752	CcSEcCtD
Loxapine—Dizziness—Epirubicin—ovarian cancer	0.000417	0.000749	CcSEcCtD
Loxapine—Pruritus—Doxorubicin—ovarian cancer	0.000413	0.000742	CcSEcCtD
Loxapine—Vomiting—Epirubicin—ovarian cancer	0.000401	0.00072	CcSEcCtD
Loxapine—Rash—Epirubicin—ovarian cancer	0.000398	0.000714	CcSEcCtD
Loxapine—Dermatitis—Epirubicin—ovarian cancer	0.000397	0.000714	CcSEcCtD
Loxapine—Headache—Epirubicin—ovarian cancer	0.000395	0.00071	CcSEcCtD
Loxapine—Dizziness—Doxorubicin—ovarian cancer	0.000386	0.000693	CcSEcCtD
Loxapine—Nausea—Epirubicin—ovarian cancer	0.000375	0.000673	CcSEcCtD
Loxapine—Vomiting—Doxorubicin—ovarian cancer	0.000371	0.000666	CcSEcCtD
Loxapine—Rash—Doxorubicin—ovarian cancer	0.000368	0.000661	CcSEcCtD
Loxapine—Dermatitis—Doxorubicin—ovarian cancer	0.000368	0.00066	CcSEcCtD
Loxapine—Headache—Doxorubicin—ovarian cancer	0.000366	0.000657	CcSEcCtD
Loxapine—Nausea—Doxorubicin—ovarian cancer	0.000347	0.000623	CcSEcCtD
Loxapine—Trifluoperazine—ABCB1—ovarian cancer	0.000301	0.0769	CrCbGaD
Loxapine—Quetiapine—ABCB1—ovarian cancer	0.000292	0.0745	CrCbGaD
Loxapine—Diazepam—ABCB1—ovarian cancer	0.000254	0.0649	CrCbGaD
Loxapine—Clozapine—ABCB1—ovarian cancer	0.000251	0.0641	CrCbGaD
Loxapine—HRH1—Signaling Pathways—CTNNB1—ovarian cancer	1.43e-05	6.75e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MMP9—ovarian cancer	1.43e-05	6.74e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—HRAS—ovarian cancer	1.42e-05	6.73e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CTNNB1—ovarian cancer	1.42e-05	6.73e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—TP53—ovarian cancer	1.42e-05	6.73e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—KRAS—ovarian cancer	1.42e-05	6.72e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—HRAS—ovarian cancer	1.42e-05	6.72e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CCND1—ovarian cancer	1.42e-05	6.71e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CTNNB1—ovarian cancer	1.42e-05	6.71e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—PTEN—ovarian cancer	1.42e-05	6.7e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CCND1—ovarian cancer	1.41e-05	6.69e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—HRAS—ovarian cancer	1.41e-05	6.68e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CXCL8—ovarian cancer	1.41e-05	6.67e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—VEGFA—ovarian cancer	1.41e-05	6.67e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CTNNB1—ovarian cancer	1.4e-05	6.64e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—TP53—ovarian cancer	1.4e-05	6.64e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MMP9—ovarian cancer	1.4e-05	6.63e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—MYC—ovarian cancer	1.4e-05	6.63e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—HRAS—ovarian cancer	1.4e-05	6.63e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CTNNB1—ovarian cancer	1.4e-05	6.62e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MMP9—ovarian cancer	1.4e-05	6.62e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—STAT3—ovarian cancer	1.4e-05	6.61e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MMP9—ovarian cancer	1.39e-05	6.6e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—PTEN—ovarian cancer	1.39e-05	6.59e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—NRAS—ovarian cancer	1.39e-05	6.59e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—PTEN—ovarian cancer	1.39e-05	6.58e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MMP9—ovarian cancer	1.39e-05	6.58e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—PIK3CA—ovarian cancer	1.39e-05	6.57e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—MYC—ovarian cancer	1.39e-05	6.57e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—VEGFA—ovarian cancer	1.39e-05	6.57e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—PTEN—ovarian cancer	1.39e-05	6.56e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—HRAS—ovarian cancer	1.38e-05	6.54e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—AKT1—ovarian cancer	1.38e-05	6.54e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—PTEN—ovarian cancer	1.38e-05	6.54e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—MAPK3—ovarian cancer	1.38e-05	6.52e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CDKN1B—ovarian cancer	1.38e-05	6.52e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MMP9—ovarian cancer	1.38e-05	6.51e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—STAT3—ovarian cancer	1.37e-05	6.5e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MMP9—ovarian cancer	1.37e-05	6.49e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—MAPK3—ovarian cancer	1.37e-05	6.49e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—MAPK1—ovarian cancer	1.37e-05	6.49e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—EGFR—ovarian cancer	1.37e-05	6.49e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—NRAS—ovarian cancer	1.37e-05	6.48e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—PTEN—ovarian cancer	1.37e-05	6.47e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—PTEN—ovarian cancer	1.37e-05	6.46e-05	CbGpPWpGaD
Loxapine—ADRA2A—GPCR downstream signaling—AKT1—ovarian cancer	1.36e-05	6.44e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—IL6—ovarian cancer	1.36e-05	6.44e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—HRAS—ovarian cancer	1.36e-05	6.44e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—IL6—ovarian cancer	1.36e-05	6.43e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—AKT1—ovarian cancer	1.36e-05	6.43e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—MAPK1—ovarian cancer	1.36e-05	6.43e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—EGFR—ovarian cancer	1.36e-05	6.43e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—AKT1—ovarian cancer	1.36e-05	6.42e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—AKT1—ovarian cancer	1.35e-05	6.4e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—IL6—ovarian cancer	1.35e-05	6.39e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CASP3—ovarian cancer	1.35e-05	6.39e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—AKT1—ovarian cancer	1.35e-05	6.38e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IL2—ovarian cancer	1.35e-05	6.38e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—TP53—ovarian cancer	1.34e-05	6.36e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—HRAS—ovarian cancer	1.34e-05	6.35e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—IL6—ovarian cancer	1.34e-05	6.34e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—MYC—ovarian cancer	1.34e-05	6.34e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—AKT1—ovarian cancer	1.34e-05	6.32e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—MAPK3—ovarian cancer	1.33e-05	6.31e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—MYC—ovarian cancer	1.33e-05	6.31e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—AKT1—ovarian cancer	1.33e-05	6.3e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—PIK3CA—ovarian cancer	1.32e-05	6.26e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—IL6—ovarian cancer	1.32e-05	6.26e-05	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—PIK3CA—ovarian cancer	1.32e-05	6.23e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CCND1—ovarian cancer	1.31e-05	6.22e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—MAPK3—ovarian cancer	1.31e-05	6.21e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—MAPK1—ovarian cancer	1.31e-05	6.21e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—EGFR—ovarian cancer	1.31e-05	6.2e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—PIK3CA—ovarian cancer	1.31e-05	6.18e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—MAPK1—ovarian cancer	1.31e-05	6.17e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—EGFR—ovarian cancer	1.31e-05	6.17e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—IL6—ovarian cancer	1.3e-05	6.16e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CTNNB1—ovarian cancer	1.3e-05	6.15e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—MYC—ovarian cancer	1.3e-05	6.14e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—KRAS—ovarian cancer	1.3e-05	6.13e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—HRAS—ovarian cancer	1.29e-05	6.08e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—IL6—ovarian cancer	1.28e-05	6.08e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—KRAS—ovarian cancer	1.28e-05	6.07e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—TP53—ovarian cancer	1.28e-05	6.06e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—VEGFA—ovarian cancer	1.28e-05	6.05e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—MYC—ovarian cancer	1.28e-05	6.04e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MMP9—ovarian cancer	1.28e-05	6.03e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—MAPK1—ovarian cancer	1.27e-05	6e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—EGFR—ovarian cancer	1.27e-05	6e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—PTEN—ovarian cancer	1.27e-05	6e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—STAT3—ovarian cancer	1.27e-05	5.99e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—NRAS—ovarian cancer	1.26e-05	5.98e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—TP53—ovarian cancer	1.26e-05	5.98e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—VEGFA—ovarian cancer	1.26e-05	5.96e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—VEGFA—ovarian cancer	1.26e-05	5.94e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—AKT1—ovarian cancer	1.26e-05	5.94e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—AKT1—ovarian cancer	1.26e-05	5.94e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—VEGFA—ovarian cancer	1.25e-05	5.92e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—MAPK1—ovarian cancer	1.25e-05	5.91e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—EGFR—ovarian cancer	1.25e-05	5.91e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—VEGFA—ovarian cancer	1.25e-05	5.91e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—AKT1—ovarian cancer	1.25e-05	5.9e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—STAT3—ovarian cancer	1.25e-05	5.9e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—STAT3—ovarian cancer	1.24e-05	5.88e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—NRAS—ovarian cancer	1.24e-05	5.88e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—NRAS—ovarian cancer	1.24e-05	5.87e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—STAT3—ovarian cancer	1.24e-05	5.87e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—KRAS—ovarian cancer	1.24e-05	5.86e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—AKT1—ovarian cancer	1.24e-05	5.85e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—NRAS—ovarian cancer	1.24e-05	5.85e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—VEGFA—ovarian cancer	1.24e-05	5.85e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—STAT3—ovarian cancer	1.24e-05	5.85e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—NRAS—ovarian cancer	1.23e-05	5.83e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—VEGFA—ovarian cancer	1.23e-05	5.83e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—KRAS—ovarian cancer	1.23e-05	5.83e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—IL6—ovarian cancer	1.23e-05	5.82e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—HRAS—ovarian cancer	1.22e-05	5.79e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—STAT3—ovarian cancer	1.22e-05	5.79e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—NRAS—ovarian cancer	1.22e-05	5.78e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—AKT1—ovarian cancer	1.22e-05	5.77e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—STAT3—ovarian cancer	1.22e-05	5.77e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—NRAS—ovarian cancer	1.22e-05	5.76e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MAPK3—ovarian cancer	1.21e-05	5.73e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—HRAS—ovarian cancer	1.21e-05	5.72e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—AKT1—ovarian cancer	1.2e-05	5.68e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—KRAS—ovarian cancer	1.2e-05	5.67e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MAPK3—ovarian cancer	1.19e-05	5.63e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—PIK3CA—ovarian cancer	1.19e-05	5.63e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MAPK3—ovarian cancer	1.19e-05	5.62e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—AKT1—ovarian cancer	1.19e-05	5.61e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MAPK3—ovarian cancer	1.18e-05	5.6e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MAPK3—ovarian cancer	1.18e-05	5.59e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—KRAS—ovarian cancer	1.18e-05	5.58e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—PIK3CA—ovarian cancer	1.18e-05	5.58e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MYC—ovarian cancer	1.18e-05	5.57e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—IL6—ovarian cancer	1.17e-05	5.54e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MAPK3—ovarian cancer	1.17e-05	5.53e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MAPK3—ovarian cancer	1.17e-05	5.52e-05	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—PIK3CA—ovarian cancer	1.17e-05	5.52e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MYC—ovarian cancer	1.16e-05	5.48e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—IL6—ovarian cancer	1.16e-05	5.47e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MYC—ovarian cancer	1.16e-05	5.47e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MYC—ovarian cancer	1.15e-05	5.45e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MAPK1—ovarian cancer	1.15e-05	5.45e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—EGFR—ovarian cancer	1.15e-05	5.45e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—TP53—ovarian cancer	1.15e-05	5.45e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MYC—ovarian cancer	1.15e-05	5.43e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—VEGFA—ovarian cancer	1.15e-05	5.42e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—TP53—ovarian cancer	1.14e-05	5.4e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—PIK3CA—ovarian cancer	1.14e-05	5.38e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MYC—ovarian cancer	1.14e-05	5.38e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—AKT1—ovarian cancer	1.14e-05	5.37e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MYC—ovarian cancer	1.13e-05	5.37e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—STAT3—ovarian cancer	1.13e-05	5.37e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MAPK1—ovarian cancer	1.13e-05	5.36e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—EGFR—ovarian cancer	1.13e-05	5.36e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—PIK3CA—ovarian cancer	1.13e-05	5.36e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—NRAS—ovarian cancer	1.13e-05	5.35e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MAPK1—ovarian cancer	1.13e-05	5.35e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—EGFR—ovarian cancer	1.13e-05	5.35e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MAPK1—ovarian cancer	1.13e-05	5.33e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—EGFR—ovarian cancer	1.13e-05	5.33e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MAPK1—ovarian cancer	1.12e-05	5.32e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—EGFR—ovarian cancer	1.12e-05	5.31e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MAPK1—ovarian cancer	1.11e-05	5.26e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—EGFR—ovarian cancer	1.11e-05	5.26e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MAPK1—ovarian cancer	1.11e-05	5.25e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—EGFR—ovarian cancer	1.11e-05	5.25e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—PIK3CA—ovarian cancer	1.1e-05	5.21e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—TP53—ovarian cancer	1.1e-05	5.21e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—HRAS—ovarian cancer	1.1e-05	5.21e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—TP53—ovarian cancer	1.1e-05	5.18e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—HRAS—ovarian cancer	1.09e-05	5.16e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—KRAS—ovarian cancer	1.09e-05	5.15e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—PIK3CA—ovarian cancer	1.08e-05	5.13e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MAPK3—ovarian cancer	1.08e-05	5.13e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—AKT1—ovarian cancer	1.08e-05	5.12e-05	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—AKT1—ovarian cancer	1.08e-05	5.09e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—KRAS—ovarian cancer	1.07e-05	5.06e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—PIK3CA—ovarian cancer	1.07e-05	5.06e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—KRAS—ovarian cancer	1.07e-05	5.05e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—AKT1—ovarian cancer	1.07e-05	5.05e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—TP53—ovarian cancer	1.07e-05	5.04e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—KRAS—ovarian cancer	1.06e-05	5.04e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—KRAS—ovarian cancer	1.06e-05	5.02e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MYC—ovarian cancer	1.05e-05	4.99e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—IL6—ovarian cancer	1.05e-05	4.98e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—HRAS—ovarian cancer	1.05e-05	4.98e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—KRAS—ovarian cancer	1.05e-05	4.97e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—TP53—ovarian cancer	1.05e-05	4.96e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—KRAS—ovarian cancer	1.05e-05	4.96e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—HRAS—ovarian cancer	1.05e-05	4.96e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—IL6—ovarian cancer	1.04e-05	4.94e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MAPK1—ovarian cancer	1.03e-05	4.88e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—EGFR—ovarian cancer	1.03e-05	4.88e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—HRAS—ovarian cancer	1.02e-05	4.82e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—IL6—ovarian cancer	1.01e-05	4.77e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—HRAS—ovarian cancer	1e-05	4.74e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—IL6—ovarian cancer	1e-05	4.74e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—PIK3CA—ovarian cancer	1e-05	4.73e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—PIK3CA—ovarian cancer	9.84e-06	4.65e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—PIK3CA—ovarian cancer	9.81e-06	4.64e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—PIK3CA—ovarian cancer	9.78e-06	4.63e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—IL6—ovarian cancer	9.76e-06	4.61e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—PIK3CA—ovarian cancer	9.75e-06	4.61e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—KRAS—ovarian cancer	9.74e-06	4.61e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—AKT1—ovarian cancer	9.72e-06	4.6e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—TP53—ovarian cancer	9.67e-06	4.57e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—PIK3CA—ovarian cancer	9.66e-06	4.57e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—AKT1—ovarian cancer	9.63e-06	4.56e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—PIK3CA—ovarian cancer	9.63e-06	4.55e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—IL6—ovarian cancer	9.6e-06	4.54e-05	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—AKT1—ovarian cancer	9.53e-06	4.51e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—TP53—ovarian cancer	9.52e-06	4.5e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—TP53—ovarian cancer	9.49e-06	4.49e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—TP53—ovarian cancer	9.46e-06	4.48e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—TP53—ovarian cancer	9.43e-06	4.46e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—TP53—ovarian cancer	9.34e-06	4.42e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—TP53—ovarian cancer	9.32e-06	4.41e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—AKT1—ovarian cancer	9.3e-06	4.4e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—AKT1—ovarian cancer	9.25e-06	4.38e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—HRAS—ovarian cancer	9.25e-06	4.37e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—HRAS—ovarian cancer	9.1e-06	4.3e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—HRAS—ovarian cancer	9.08e-06	4.29e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—HRAS—ovarian cancer	9.05e-06	4.28e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—HRAS—ovarian cancer	9.02e-06	4.27e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—AKT1—ovarian cancer	9e-06	4.26e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—PIK3CA—ovarian cancer	8.95e-06	4.23e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—HRAS—ovarian cancer	8.93e-06	4.23e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—HRAS—ovarian cancer	8.91e-06	4.21e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—AKT1—ovarian cancer	8.86e-06	4.19e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—IL6—ovarian cancer	8.85e-06	4.19e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—AKT1—ovarian cancer	8.74e-06	4.13e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—IL6—ovarian cancer	8.71e-06	4.12e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—IL6—ovarian cancer	8.69e-06	4.11e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—IL6—ovarian cancer	8.66e-06	4.1e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—TP53—ovarian cancer	8.66e-06	4.09e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—IL6—ovarian cancer	8.64e-06	4.08e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—IL6—ovarian cancer	8.55e-06	4.04e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—IL6—ovarian cancer	8.53e-06	4.03e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—HRAS—ovarian cancer	8.28e-06	3.92e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—AKT1—ovarian cancer	8.17e-06	3.86e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—AKT1—ovarian cancer	8.03e-06	3.8e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—AKT1—ovarian cancer	8.02e-06	3.79e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—AKT1—ovarian cancer	7.99e-06	3.78e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—AKT1—ovarian cancer	7.97e-06	3.77e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IL6—ovarian cancer	7.92e-06	3.75e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—AKT1—ovarian cancer	7.89e-06	3.73e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—AKT1—ovarian cancer	7.87e-06	3.72e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—AKT1—ovarian cancer	7.31e-06	3.46e-05	CbGpPWpGaD
